Investors & Media

Corporate Profile

Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company. More than 100 million Americans suffer from chronic or acute pain, while another 100 million suffer from various neurological disorders, including migraines, low back pain and neck pain.1 Pain medications are often used to help treat these conditions.

Many patients experiencing moderate to severe pain receive prescription opioids, though treatment with opioids comes with inherent risks. Neumentum’s analgesic product candidates have the potential to provide the benefits of safe and effective pain management without the limitations and risks for abuse and misuse that come with opioids.

Neumentum is led by a world-class executive team of biotech and pharmaceutical industry leaders who have extensive pain and neurology experience, from drug development through commercialization. Neumentum has global rights to five novel non-opioid pain products, the most advanced of which are two phase 3-ready injectable products under development for acute postsurgical pain.

Neumentum’s Taggart McGurrin Awarded Rising Star in Accounting and Finance by Life Sciences Leaders and Stars

(Morristown, NJ - October 15, 2021) – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids, is pleased to announce that Taggart McGurrin, Neumentum’s Chief Business Officer, has won the Rising Star Award from the...

Neumentum and NEMA Research Inc. Named to Short-List of Citeline Awards for 2021

Nominated for Most Successful Early-Phase Research (Morristown, NJ - September 20, 2021) – The Citeline Awards, sponsored by Informa Pharma Intelligence, today announced that Neumentum Inc. and NEMA Research, Inc., have been nominated and are in consideration for an...